These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6202398)

  • 1. Enhanced lymphatic delivery of mitomycin C conjugated with dextran.
    Takakura Y; Matsumoto S; Hashida M; Sezaki H
    Cancer Res; 1984 Jun; 44(6):2505-10. PubMed ID: 6202398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.
    Hashida M; Kato A; Takakura Y; Sezaki H
    Drug Metab Dispos; 1984; 12(4):492-9. PubMed ID: 6148218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
    Honda K; Satomura K; Hashida M; Sezaki H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):530-5. PubMed ID: 2408576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion characteristics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate.
    Takakura Y; Kato A; Hashida M; Honda K; Arimoto A; Satomura K; Sezaki H
    J Pharmacobiodyn; 1985 May; 8(5):357-64. PubMed ID: 2413196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary excretion of mitomycin C dextran conjugates in relation to physicochemical characteristics of carrier dextran.
    Hashida M; Atsumi R; Nishida K; Nakane S; Takakura Y; Sezaki H
    J Pharmacobiodyn; 1990 Jul; 13(7):441-7. PubMed ID: 1705289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate.
    Matsumoto S; Yamamoto A; Takakura Y; Hashida M; Tanigawa N; Sezaki H
    Cancer Res; 1986 Sep; 46(9):4463-8. PubMed ID: 2425952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.
    Hashida M; Kato A; Kojima T; Muranishi S; Sezaki H; Tanigawa N; Satomura K; Hikasa Y
    Gan; 1981 Apr; 72(2):226-34. PubMed ID: 6169584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the perfused rat liver.
    Sato K; Itakura K; Nishida K; Takakura Y; Hashida M; Sezaki H
    J Pharm Sci; 1989 Jan; 78(1):11-6. PubMed ID: 2468759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and tumor localization of mitomycin C-dextran conjugates in mice.
    Takakura Y; Takagi A; Hashida M; Sezaki H
    Pharm Res; 1987 Aug; 4(4):293-300. PubMed ID: 2470072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C.
    Kojima T; Hashida M; Muranishi S; Sezaki H
    J Pharm Pharmacol; 1980 Jan; 32(1):30-4. PubMed ID: 6102123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits.
    Atsumi R; Endo K; Kakutani T; Takakura Y; Hashida M; Sezaki H
    Cancer Res; 1987 Nov; 47(21):5546-51. PubMed ID: 2444332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The accumulation mechanism of cationic mitomycin C-dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes.
    Nakane S; Matsumoto S; Takakura Y; Hashida M; Sezaki H
    J Pharm Pharmacol; 1988 Jan; 40(1):1-6. PubMed ID: 2452868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption characteristics of the lipophilic prodrug of mitomycin C from injected liposomes or an emulsion.
    Sasaki H; Kakutani T; Hashida M; Sezaki H
    J Pharm Pharmacol; 1985 Jul; 37(7):461-5. PubMed ID: 2863347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection.
    Nomura T; Saikawa A; Morita S; Sakaeda Kakutani T; Yamashita F; Honda K; Takakura Y; Hashida M
    J Control Release; 1998 Mar; 52(3):239-52. PubMed ID: 9743445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemocoagulation of metastatic lymph nodes using a suspension of mitomycin C-adsorbing activated carbon particles in 80% ethanol.
    Seiki K; Takahashi T; Sawai K; Okano S; Hagiwara A
    Cancer Invest; 1993; 11(4):379-87. PubMed ID: 8324642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and excretion of 7-N-(p-hydroxyphenyl)-mitomycin C in normal mice.
    Imai R; Morimoto M; Marumo H
    Gan; 1982 Aug; 73(4):675-80. PubMed ID: 6818093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pre-operative endoscopic infusions of an adsorbent containing mitomycin C (MMC-CH44) in stomach cancer].
    Hagiwara A; Takahashi T; Ueda T; Takeda M; Lee R; Mizuguchi N
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2558-64. PubMed ID: 6418078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A newly developed drug delivery system using fine particles of activated charcoal for targeting chemotherapy.
    Ito K; Kiriyama K; Watanabe T; Yamauchi M; Akiyama S; Kondou K; Takagi H
    ASAIO Trans; 1990; 36(3):M199-202. PubMed ID: 2123633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
    Fujita H
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1362-73. PubMed ID: 6820913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macromolecule-drug conjugates in targeted cancer chemotherapy.
    Sezaki H; Hashida M
    Crit Rev Ther Drug Carrier Syst; 1984; 1(1):1-38. PubMed ID: 6085861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.